厄贝沙坦对原发性高血压的疗效及对心率变异性的影响  

Effects of Irosartan on essential hypertension and heart rate variability

作　　者：吴奇志[1] 

机构地区：[1]厦门大学附属中山医院湖里分院心内科,福建厦门361006

出　　处：《中国医药导报》2010年第3期73-74,共2页China Medical Herald

摘　　要：目的:观察厄贝沙坦(Irosartan)对原发性高血压患者的降压作用及其对变异性的影响。方法:43例原发性高血压患者服安慰剂2周后,服厄贝沙坦150～300mg/d,共8周。治疗前和治疗8周后行24h动态心电图检查和24h动态血压监测。结果:厄贝沙坦能明显降低血压;使时域指标SDNN[(118.4±28.3)msvs(128.6±33.6)ms,P<0.05]、SDANN[(100.2±26.5)msvs(116.3±23.8)ms,P<0.05)]和SDNNI[(42.3±15.7)msvs(51.2±16.7)ms,P<0.05)]升高;RMSSD和PNN50轻度升高;频域指标VLF[(1832.5±836.5)Hzvs(1522.6±731.4)Hz,P<0.05)]和LF[(455.3±256.8)Hzvs(402.5±112.4)Hz,P<0.05)]下降,HF[(112.5±86.4)Hzvs(198.6±97.8)Hz,P<0.05)]增加。结论:厄贝沙坦对原发性高血压患者降压的同时,对心率变异性产生有益作用。Objective：To observe the effect of Irosartan on essential hypertension and the heart rate variability.Methods：After 2 weeks washout period,43 patients with Irosartan mild to moderate hypertension received once-daily 150-300 mg for 8 weeks.The 24 hour ambulatory ECG and 24 hour ambulatory blood pressure monitoring were performed before and after 8 weeks treatment.Results：DBP and SBP were obviously decreased;SDNN[（118.4±28.3） ms vs （128.6±33.6） ms,P0.05],SDANN[（100.2±26.5）ms vs （116.3±23.8） ms,P0.05）] and SDNNI[（42.3±15.7） ms vs （51.2±16.7） ms,P0.05）] were increased;RMSSD and PNN50 increased;in association with the increases in HF [（112.5±86.4） Hz vs （198.6±97.8） Hz,P0.05）],the VLF[（1 832.5±836.5）Hz vs （1 522.6±731.4） Hz,P0.05）] and LF[（455.3±256.8） Hz vs （402.5±112.4） Hz,P0.05）] were decreased.Conclusion：Irosartan not only decreases blood pressure but also shows beneficial effect on HRV.

关 键 词：心率变异性 原发性高血压 厄贝沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]